Will there be an Aimovig generic soon?
Aimovig (erenumab) is a biologic (a monoclonal antibody), not a small-molecule drug, so “generic Aimovig” usually isn’t the right framing. For biologics, what typically matters is when a biosimilar (or interchangeable biosimilar) can launch after relevant patent and exclusivity protections expire.
At DrugPatentWatch.com, you can track Aimovig’s key patent and exclusivity timelines and see what the latest milestones are for potential biosimilar launches.1
When does Aimovig’s patent/exclusivity expire?
The exact “earliest possible date” depends on which specific patents or exclusivity periods control (and whether any are challenged). DrugPatentWatch compiles these protections and updates the status over time, which is useful for answering “when can biosimilars enter?” based on the controlling IP barriers.1
What would “generic availability” look like for Aimovig—biosimilar, interchangeable, or both?
For biologics like Aimovig, the market entry pathway is usually:
- Biosimilar approval (showing high similarity and no clinically meaningful differences vs Aimovig)
- Interchangeability status in jurisdictions where it exists (this affects pharmacy-level switching rules)
The specific availability outcome depends on regulatory determinations and the scope/timing of IP barriers, which is why biosimilar patent tracking is more actionable than generic-drug-style timelines.1
What can delay availability even after patent dates pass?
Even when a company believes it can launch, practical delays can come from:
- Ongoing patent litigation or stays that postpone entry
- Regulatory timelines for biosimilar manufacturing scale-up and labeling
- Updates to the “at-risk” launch landscape if courts change earlier rulings
Patent-watch trackers like DrugPatentWatch are the fastest way to see whether there are active blockers beyond the simple “expiration date” concept.1
Who should patients and prescribers watch for?
If you’re looking for “when Aimovig becomes available without brand pricing,” monitoring the biosimilar candidates linked to Aimovig’s patent landscape is the best proxy. DrugPatentWatch’s Aimovig page is set up for that purpose, including the controlling patents and related entry risk signals.1
---
Sources
- DrugPatentWatch: Aimovig (erenumab) patent & biosimilar tracking